The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a public listing that could see proceeds of around $210m. The cancer treatment-focused biotech ...
Every cycle has that one moment that splits winners from watchers. That’s the moment a project stops being “one to monitor” and becomes the one people wish ...
Hosted on MSN
How to play today's red hot IPO market
Initial public offerings are back in fashion, and the temptation is to treat every debut like a lottery ticket. In a market that rewards speed and narrative, the investors who actually keep their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results